02 December 2002
Physicians and Pharmaceutical Industry
Zbigniew GaciongAnn Transplant 2002; 7(4): 15-15 :: ID: 496257
Abstract
Relationships between academic medical institutions as well as individual physicians have been vigorously debated in media and within the medical society during last years. Recently, European Federation of Internal Medicine, the ACP-ASIM Foundation, and the ABIM Foundation have developed a “physician’s charter” a sort of contemporary Hippocrates’s oath, to encompass a set of principles to which all medical professionals can and should aspire (1).
Keywords: Organ Transplantation, pharmaceutical industry, Clinical Trials
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860